The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain

Greeley JD, Lê AD, Poulos CX, Cappell H (1988) "Paradoxical" analgesia induced by naloxone and naltrexone. Psychopharmacology (Berlin) 96(1):36–39

Burns LH, Wang HY (2010) Ultra-low-dose naloxone or naltrexone to improve opioid analgesia: the history, the mystery and a novel approach clinical medicine insights

Davis M, Goforth HW, Gamier P (2013) Oxycodone combined with opioid receptor antagonists: efficacy and safety. Expert Opin Drug Saf 12(3):389–402

Resnick RB, Volavka J, Freedman AM, Thomas M (1974) Studies of EN-1639A (naltrexone): a new narcotic antagonist. Am J Psychiatry 131(6):646–650

Verebey K, Mulé SJ (1975) Naltrexone pharmacology, pharmacokinetics, and metabolism: current status. Am J Drug Alcohol Abuse 2(3–4):357–363

Gold MS, Dackis CA, Pottash AL, Sternbach HH, Annitto WJ, Martin D, Dackis MP (1982) Naltrexone, opiate addiction, and endorphins. Med Res Rev 2(3):211–246

Smith JP, Bingaman SI, Ruggiero F, Mauger DT, Mukherjee A, McGovern CO, Zagon IS (2011) Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn’s disease: a randomized placebo-controlled trial. Dig Dis Sci 56(7):2088–2097

Cree BA, Kornyeyeva E, Goodin DS (2010) Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. Ann Neurol 68(2):145–150

Younger J, Noor N, McCue R, Mackey S (2013) Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum 65(2):529–538

Bihari B (2013) Bernard Bihari, MD: low-dose naltrexone for normalizing immune system function. Altern Ther Health Med 19(2):56–65

Zagon IS, McLaughlin PJ (1989) Opioid antagonist modulation of murine neuroblastoma: a profile of cell proliferation and opioid peptides and receptors. Brain Res 480(1–2):16–28

Smith JP, Stock H, Bingaman S, Mauger D, Rogosnitzky M, Zagon IS (2007) Low-dose naltrexone therapy improves active Crohn’s disease. Am J Gastroenterol 102(4):820–828

Clauw DJ, Arnold LM, McCarberg BH, FibroCollaborative (2011) The science of fibromyalgia. Mayo Clin Proc 86(9):907–911

Wallace DJ (2006) Is there a role for cytokine based therapies in fibromyalgia. Curr Pharm Des 12(1):17–22

Younger J, Mackey S (2009) Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Med 10(4):663–672

Wang D, Sun X, Sadee W (2007) Different effects of opioid antagonists on mu-, delta-, and kappa-opioid receptors with and without agonist pretreatment. J Pharmacol Exp Ther 321(2):544–552

Watkins LR, Hutchinson MR, Ledeboer A, Wieseler-Frank J, Milligan ED, Maier SF (2007) Norman cousins lecture. Glia as the "bad guys": implications for improving clinical pain control and the clinical utility of opioids. Brain Behav Immun 21(2):131–146

McCusker RH, Kelley KW (2013) Immune-neural connections: how the immune system’s response to infectious agents influences behavior. J Exp Biol 216(Pt 1):84–98

Dantzer R (2007) Twenty years of research on cytokine-induced sickness behavior Brain, behavior, and immunity

Kelley KW, Bluthé RM, Dantzer R, Zhou JH, Shen WH, Johnson RW, Broussard SR (2003) Cytokine-induced sickness behavior. Brain Behav Immun 17(Suppl 1):S112–S118

Wieseler-Frank J, Maier SF, Watkins LR (2005) Immune-to-brain communication dynamically modulates pain: physiological and pathological consequences. Brain Behav Immun 19(2):104–111

Hutchinson MR et al (2008) Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4). Eur J Neurosci 28(1):20–29

Liu B, Du L, Hong JS (2000) Naloxone protects rat dopaminergic neurons against inflammatory damage through inhibition of microglia activation and superoxide generation. J Pharmacol Exp Ther 293(2):607–617

Chang RC, Rota C, Glover RE, Mason RP, Hong JS (2000) A novel effect of an opioid receptor antagonist, naloxone, on the production of reactive oxygen species by microglia: a study by electron paramagnetic resonance spectroscopy. Brain Res 854(1–2):224–229

Liu SL, Li YH, Shi GY, Chen YH, Huang CW, Hong JS, Wu HL (2006) A novel inhibitory effect of naloxone on macrophage activation and atherosclerosis formation in mice. J Am Coll Cardiol 48(9):1871–1879

Valentino RJ, Katz JL, Medzihradsky F, Woods JH (1983) Receptor binding, antagonist, and withdrawal precipitating properties of opiate antagonists. Life Sci 32(25):2887–2896

Lewis SS, Loram LC, Hutchinson MR, Li CM, Zhang Y, Maier SF, Huang Y, Rice KC, Watkins LR (2012) (+)-naloxone, an opioid-inactive toll-like receptor 4 signaling inhibitor, reverses multiple models of chronic neuropathic pain in rats. J Pain 13(5):498–506

Stevens CW, Aravind S, Das S, Davis RL (2013) Pharmacological characterization of LPS and opioid interactions at the toll-like receptor 4. Br J Pharmacol 168(6):1421–1429

Fukagawa H, Koyama T, Kakuyama M, Fukuda K (2013) Microglial activation involved in morphine tolerance is not mediated by toll-like receptor 4. J Anesth 27(1):93–97

Block L, Björklund U, Westerlund A, Jörneberg P, Biber B, Hansson E (2013) A new concept affecting restoration of inflammation-reactive astrocytes. Neuroscience 250:536–545

Wang Q, Zhou H, Gao H, Chen SH, Chu CH, Wilson B, Hong JS (2012) Naloxone inhibits immune cell function by suppressing superoxide production through a direct interaction with gp91phox subunit of NADPH oxidase. J Neuroinflammation 9:32

Zagon IS, Verderame MF, McLaughlin PJ (2002) The biology of the opioid growth factor receptor (OGFr). Brain Res Brain Res Rev 38(3):351–376

Sharma R, Rauchhaus M, Ponikowski PP, Varney S, Poole-Wilson PA, Mann DL, Coats AJ, Anker SD (2000) The relationship of the erythrocyte sedimentation rate to inflammatory cytokines and survival in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 36(2):523–528

García JJ, Cidoncha A, Bote ME, Hinchado MD, Ortega E (2013) Altered profile of chemokines in fibromyalgia patients. Ann Clin Biochem 6(7):425–435

Xiao Y, Haynes WL, Michalek JE, Russell IJ (2013) Elevated serum high-sensitivity C-reactive protein levels in fibromyalgia syndrome patients correlate with body mass index, interleukin-6, interleukin-8, erythrocyte sedimentation rate. Rheumatol Int 33(5):1259–1264

Smith JP, Field D, Bingaman SI, Evans R, Mauger DT (2013) Safety and tolerability of low-dose naltrexone therapy in children with moderate to severe Crohn’s disease: a pilot study. J Clin Gastroenterol 47(4):339–345

Sharafaddinzadeh N, Moghtaderi A, Kashipazha D, Majdinasab N, Shalbafan B (2010) The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial. Mult Scler 16(8):964–969

Chopra P, Cooper MS (2013) Treatment of complex regional pain syndrome (CRPS) using low dose naltrexone (LDN). J Neuroimmune Pharm 8(3):470–476

Parkitny L, McAuley JH, Di Pietro F, Stanton TR, O’Connell NE, Marinus J, van Hilten JJ, Moseley GL (2013) Inflammation in complex regional pain syndrome: a systematic review and meta-analysis. Neurology 80(1):106–117

Brown N, Panksepp J (2009) Low-dose naltrexone for disease prevention and quality of life. Med Hypotheses 72(3):333–337

Tempel A, Gardner EL, Zukin RS (1985) Neurochemical and functional correlates of naltrexone-induced opiate receptor up-regulation. J Pharmacol Exp Ther 232(2):439–444

Zagon IS, McLaughlin PJ (1995) Gene-peptide relationships in the developing rat brain: the response of preproenkephalin mRNA and [Met5]-enkephalin to acute opioid antagonist (naltrexone) exposure. Brain Res Mol Brain Res 33(1):111–120

Donahue RN, McLaughlin PJ, Zagon IS (2011) Low-dose naltrexone targets the opioid growth factor-opioid growth factor receptor pathway to inhibit cell proliferation: mechanistic evidence from a tissue culture model. Exp Biol Med (Maywood) 236(9):1036–1050

Kayser V, Besson JM, Guilbaud G (1987) Paradoxical hyperalgesic effect of exceedingly low doses of systemic morphine in an animal model of persistent pain (Freund’s adjuvant-induced arthritic rats). Brain Res 414(1):155–157

Galeotti N, Stefano GB, Guarna M, Bianchi E, Ghelardini C (2006) Signaling pathway of morphine induced acute thermal hyperalgesia in mice. Pain 123(3):294–305

Physicians’ Desk Reference 2013 (67th ed) Montvale, NJ: PDR

Pini LA, Ferretti C, Trenti T, Ferrari A, Sternieri E (1991) Effects of long-term treatment with naltrexone on hepatic enzyme activity. Drug Metabol Drug Interact 9(2):161–174

Zagon IS, Donahue R, McLaughlin PJ (2013) Targeting the opioid growth factor: opioid growth factor receptor axis for treatment of human ovarian cancer. Exp Biol Med (Maywood) 238(5):579–587

Casha S, Zygun D, McGowan MD, Bains I, Yong VW, Hurlbert RJ (2012) Results of a phase II placebo-controlled randomized trial of minocycline in acute spinal cord injury. Brain 135(Pt 4):1224–1236

Zhou Q, Price DD, Callam CS, Woodruff MA, Verne GN (2011) Effects of the N-methyl-D-aspartate receptor on temporal summation of second pain (wind-up) in irritable bowel syndrome. J Pain 12(2):297–303

Swift RM (2013) Naltrexone and nalmefene: any meaningful difference? Biol Psychiatry 73(8):700–701

Tang C, Godfrey T, Stawell R, Nikpour M (2012) Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects. Int Med J 42(9):968–978

Steere AC, Angelis SM (2006) Therapy for Lyme arthritis: strategies for the treatment of antibiotic-refractory arthritis. Arthritis Rheum 54(10):3079–3086

Choi DK, Koppula S, Suk K (2011) Inhibitors of microglial neurotoxicity: focus on natural products. Molecules 16(2):1021–1043

Moore A, Wilkinson S (2009) The promise of low dose naltrexone. McFarland, North Carolina